Medarex acquires technology and antibody product development programmes from Corixa
By Business Review Editor
Pharma Deals Review: Vol 2002 Issue 25 (Table of Contents)
Published: 2 Jun-2002
DOI: 10.3833/pdr.v2002.i25.1045 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Medarex acquired Corixa’s ultra-potent toxin technology and certain preclinical antibody development programmes in oncology and other disease indications...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS